Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62nd year of consecutive increases.
At the new rate, the indicated dividend on an annual basis is $4.96 per share compared to the previous rate of $4.76 per share. The next quarterly dividend is payable on June 4, 2024 to shareholders of record at the close of business on May 21, 2024. The ex-dividend date is May 20, 2024.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.
Workers at the Marin/Sonoma Mosquito and Vector Control District have voted unanimously to join Teamsters Local 665. The 33 new members protect the health and welfare of residents in Marin and Sonoma counties from mosquitoes and vector-borne...
Sera Prognostics Inc., The Pregnancy Company® , focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2024...
"I'm employed as a phlebotomist, and I wanted to create a faster means to draw blood when multiple tubes are required," said an inventor, from Rockton, Ill., "so I invented the PHLEBOTOMY TUBE HOLDER. My design ensures that phlebotomy tubes and a...
Life Time today announced the appointment of James LaValle, clinical pharmacist, C.C.N.M.T. as Chief Science Officer. LaValle will spearhead the development and implementation of scientific initiatives and strategic relationships to support MIORA,...
Stratus® Medical, a company focused on improving clinical outcomes for chronic pain patients by advancing radiofrequency (RF) technology for the treatment of pain, announced today the expansion of patent protection in Europe for its NIMBUS®...
The push for a transformative U.S.-India partnership in newborn screening (NBS) sets the stage for a seismic shift in tackling rare diseases, spotlighting the need to prepare for the digital AI revolution in global healthcare. Advocates are rallying...
